Analysts rave over Biogen MS pill on second Phase III success Pharma Times Dr O'Neill also highlighted the promise being shown by PEG-Avonex and Abbott-partnered daclizumab, both of which are expected to report Phase III data in 2013. The company is also extremely excited about the potential for Anti-Lingo, which is in Phase ... |
